NZ706541A - Compositions and methods for immunotherapy - Google Patents

Compositions and methods for immunotherapy

Info

Publication number
NZ706541A
NZ706541A NZ706541A NZ70654113A NZ706541A NZ 706541 A NZ706541 A NZ 706541A NZ 706541 A NZ706541 A NZ 706541A NZ 70654113 A NZ70654113 A NZ 70654113A NZ 706541 A NZ706541 A NZ 706541A
Authority
NZ
New Zealand
Prior art keywords
cells
methods
immunotherapy
compositions
antigen
Prior art date
Application number
NZ706541A
Other languages
English (en)
Inventor
Christopher C Kloss
Michel Sadelain
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50435409&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ706541(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Priority to NZ746914A priority Critical patent/NZ746914A/en
Publication of NZ706541A publication Critical patent/NZ706541A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001109—Vascular endothelial growth factor receptors [VEGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A61K39/001113—CD22, BL-CAM, siglec-2 or sialic acid- binding Ig-related lectin 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A61K39/001114—CD74, Ii, MHC class II invariant chain or MHC class II gamma chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001116—Receptors for cytokines
    • A61K39/001117—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR] or CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001116—Receptors for cytokines
    • A61K39/001119—Receptors for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001124—CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001128—CD44 not IgG
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K39/001168—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A61K39/001182—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001195—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4274—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4274—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A61K40/4276—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2999/00—Further aspects of viruses or vectors not covered by groups C12N2710/00 - C12N2796/00 or C12N2800/00
    • C12N2999/002—Adverse teaching

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Reproductive Health (AREA)
  • Biotechnology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
NZ706541A 2012-10-02 2013-10-02 Compositions and methods for immunotherapy NZ706541A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ746914A NZ746914A (en) 2012-10-02 2013-10-02 Compositions and methods for immunotherapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261709072P 2012-10-02 2012-10-02
PCT/US2013/063097 WO2014055668A1 (en) 2012-10-02 2013-10-02 Compositions and methods for immunotherapy

Publications (1)

Publication Number Publication Date
NZ706541A true NZ706541A (en) 2019-07-26

Family

ID=50435409

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ706541A NZ706541A (en) 2012-10-02 2013-10-02 Compositions and methods for immunotherapy
NZ746914A NZ746914A (en) 2012-10-02 2013-10-02 Compositions and methods for immunotherapy

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ746914A NZ746914A (en) 2012-10-02 2013-10-02 Compositions and methods for immunotherapy

Country Status (16)

Country Link
US (4) US10654928B2 (cg-RX-API-DMAC7.html)
EP (2) EP2903637B1 (cg-RX-API-DMAC7.html)
JP (5) JP6441802B2 (cg-RX-API-DMAC7.html)
KR (1) KR102198058B1 (cg-RX-API-DMAC7.html)
CN (3) CN112458057A (cg-RX-API-DMAC7.html)
AU (3) AU2013327136A1 (cg-RX-API-DMAC7.html)
CA (1) CA2886859C (cg-RX-API-DMAC7.html)
ES (1) ES2743738T3 (cg-RX-API-DMAC7.html)
IL (2) IL238047B (cg-RX-API-DMAC7.html)
MX (1) MX370148B (cg-RX-API-DMAC7.html)
NZ (2) NZ706541A (cg-RX-API-DMAC7.html)
PH (2) PH12015500747B1 (cg-RX-API-DMAC7.html)
RU (1) RU2729401C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201502598SA (cg-RX-API-DMAC7.html)
WO (1) WO2014055668A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201502880B (cg-RX-API-DMAC7.html)

Families Citing this family (355)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2817331B1 (en) 2012-02-22 2023-08-30 The Trustees of the University of Pennsylvania Use of the cd2 signaling domain in second-generation chimeric antigen receptors
EP2903637B1 (en) 2012-10-02 2019-06-12 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
US10117896B2 (en) 2012-10-05 2018-11-06 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
ES2776698T3 (es) 2012-12-20 2020-07-31 Purdue Research Foundation Células T que expresan un receptor antigénico quimérico como terapia contra el cáncer
WO2014117121A1 (en) 2013-01-28 2014-07-31 St. Jude Children's Research Hospital, Inc. A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
KR102417657B1 (ko) * 2013-02-06 2022-07-07 안트로제네시스 코포레이션 개선된 특이성을 갖는 변경된 t 림프구
EP3811954A1 (en) 2013-02-26 2021-04-28 Memorial Sloan Kettering Cancer Center Compositions and methods for immunotherapy
AU2014240083C1 (en) 2013-03-15 2019-10-24 Celgene Corporation Modified T lymphocytes
WO2014165707A2 (en) * 2013-04-03 2014-10-09 Memorial Sloan-Kettering Cancer Center Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
EP3105333B1 (en) * 2014-02-10 2020-04-08 Emory University Expression of chimeric polypeptide with variable lymphocyte receptors on immune cells and uses for treating cancer
NZ739448A (en) 2014-04-10 2019-10-25 Seattle Children’S Hospital Dba Seattle Children’S Res Institute Transgene genetic tags and methods of use
RU2763795C2 (ru) 2014-04-23 2022-01-11 Джуно Терапьютикс, Инк. Способы выделения, культивирования и генетической инженерии популяций клеток иммунной системы для адоптивной терапии
AU2015249376C1 (en) 2014-04-25 2019-10-31 2Seventy Bio, Inc. Improved methods for manufacturing adoptive cell therapies
WO2015164759A2 (en) 2014-04-25 2015-10-29 Bluebird Bio, Inc. Mnd promoter chimeric antigen receptors
CA2948462A1 (en) 2014-05-15 2015-11-19 National University Of Singapore Modified natural killer cells and uses thereof
AU2015269219B2 (en) 2014-06-06 2020-12-24 Memorial Sloan-Kettering Cancer Center Mesothelin-targeted chimeric antigen receptors and uses thereof
SG11201610170SA (en) * 2014-06-06 2017-01-27 Bluebird Bio Inc Improved t cell compositions
AU2015289644A1 (en) 2014-07-15 2017-02-02 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
US10174095B2 (en) 2014-07-21 2019-01-08 Novartis Ag Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor
SG11201700416TA (en) 2014-07-21 2017-02-27 Novartis Ag Treatment of cancer using a cd33 chimeric antigen receptor
CA2956002C (en) 2014-07-24 2023-06-27 Bluebird Bio, Inc. Bcma chimeric antigen receptors
PL3177640T3 (pl) 2014-08-08 2020-11-02 The Board Of Trustees Of The Leland Stanford Junior University Charakteryzujące się wysokim powinowactwem środki terapeutyczne naśladujące PD-11 i sposoby ich wykorzystania
TWI751102B (zh) 2014-08-28 2022-01-01 美商奇諾治療有限公司 對ｃｄ１９具專一性之抗體及嵌合抗原受體
ES2688035T3 (es) * 2014-08-29 2018-10-30 Gemoab Monoclonals Gmbh Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes
IL293714A (en) 2014-10-20 2022-08-01 Juno Therapeutics Inc Methods and compositions for dosing in adoptive cell therapy
EP4653013A2 (en) * 2014-10-31 2025-11-26 The Trustees of the University of Pennsylvania Methods and compositions for modified t cells
SG10202002324SA (en) 2014-11-05 2020-05-28 Juno Therapeutics Inc Methods for transduction and cell processing
WO2016090190A1 (en) 2014-12-03 2016-06-09 Juno Therapeutics, Inc. Methods and compositions for adoptive cell therapy
AU2015360845B2 (en) 2014-12-12 2020-11-26 2Seventy Bio, Inc. BCMA chimeric antigen receptors
KR102376244B1 (ko) 2014-12-24 2022-03-21 오토러스 리미티드 세포
MA41346A (fr) 2015-01-12 2017-11-21 Juno Therapeutics Inc Eléments régulateurs post-transcriptionnels d'hépatite modifiée
US20160208018A1 (en) 2015-01-16 2016-07-21 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for ror1
AU2016211671B2 (en) 2015-01-26 2022-05-26 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
AU2016222887B2 (en) 2015-02-24 2022-07-14 The Regents Of The University Of California Binding-triggered transcriptional switches and methods of use thereof
IL254141B (en) 2015-02-27 2022-07-01 Icell Gene Therapeutics Llc Chimeric antigen receptors (cars) focusing on hematological malignancies, preparations and methods for their use
JP6890546B2 (ja) * 2015-04-02 2021-06-18 メモリアル スローン ケタリング キャンサー センター Ｔｎｆｒｓｆ１４／ｈｖｅｍタンパク質およびその使用の方法
HUE059218T2 (hu) 2015-04-08 2022-11-28 Novartis Ag CD20-terápiák, CD22-terápiák és kombinációs terápiák CD19 kiméra antigénreceptort (CAR-t) expresszáló sejttel
KR20180021364A (ko) * 2015-04-15 2018-03-02 프로스펙트 차터케어 알더블유엠씨, 엘엘씨 디/비/에이 로저 윌리암스 메디컬 센터 Car-t 세포의 간 동맥 주입
WO2016166568A1 (en) 2015-04-16 2016-10-20 Juno Therapeutics Gmbh Methods, kits and apparatus for expanding a population of cells
US11896614B2 (en) 2015-04-17 2024-02-13 Novartis Ag Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
MA41962A (fr) 2015-04-23 2018-02-28 Baylor College Medicine Récepteur antigénique chimérique ciblant le cd5 pour une thérapie adoptive à base de cellules t
KR20180021685A (ko) 2015-04-25 2018-03-05 더 제너럴 하스피털 코포레이션 암 치료용 항-기피주성제와 항암제 조합 요법 및 조성물
CN114634943A (zh) 2015-05-18 2022-06-17 T细胞受体治疗公司 使用融合蛋白对tcr重编程的组合物和方法
CN108174607A (zh) 2015-05-29 2018-06-15 朱诺治疗学股份有限公司 用于遗传工程改造的细胞中调节抑制性相互作用的组合物和方法
KR102526538B1 (ko) * 2015-06-10 2023-04-28 이뮤너티바이오, 인크. 암을 치료하기 위한 변형된 nk-92 세포
US11173179B2 (en) 2015-06-25 2021-11-16 Icell Gene Therapeutics Llc Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
TW202444897A (zh) 2015-06-25 2024-11-16 美商生物細胞基因治療有限公司 嵌合抗原受體(car)、組合物及其使用方法
MA42895A (fr) 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
SG10201912978PA (en) * 2015-07-21 2020-02-27 Novartis Ag Methods for improving the efficacy and expansion of immune cells
WO2017023859A1 (en) * 2015-07-31 2017-02-09 Memorial Sloan-Kettering Cancer Center Antigen-binding proteins targeting cd56 and uses thereof
GB201513540D0 (en) * 2015-07-31 2015-09-16 King S College London Therapeutic agents
WO2017027291A1 (en) * 2015-08-07 2017-02-16 Seattle Children's Hospital (dba Seattle Children's Research Institute) Bispecific car t-cells for solid tumor targeting
CN105087495B (zh) * 2015-08-21 2016-04-27 深圳市茵冠生物科技有限公司 双嵌合抗原受体修饰的t淋巴细胞及其制备方法
CA2997551A1 (en) 2015-09-04 2017-03-09 Memorial Sloan Kettering Cancer Center Immune cell compositions and methods of use
CA2999083A1 (en) 2015-09-18 2017-03-23 The General Hospital Corporation Dba Massachusetts General Hospital Localized delivery of anti-fugetactic agent for treatment of cancer
RU2757135C2 (ru) 2015-09-24 2021-10-11 АБВИТРО ЭлЭлСи Композиции антител к вич и способы их применения
CN105924529B (zh) * 2015-10-13 2019-08-06 中国人民解放军总医院 嵌合抗原受体及其基因和重组表达载体、car138-nkt细胞及其制备方法和应用
MA45488A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés, kits et appareil de culture de cellules
MA45489A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés de culture de cellules, kits et appareil associés
WO2017068419A2 (en) 2015-10-22 2017-04-27 Juno Therapeutics Gmbh Methods, kits, agents and apparatuses for transduction
CN107614519B (zh) 2015-10-23 2022-08-05 优瑞科生物技术公司 抗体/t细胞受体嵌合构建体及其用途
PT3371314T (pt) 2015-11-04 2023-08-31 Fate Therapeutics Inc Modificação genómica de células pluripotentes
CA3003152A1 (en) 2015-11-04 2017-05-11 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
US11020429B2 (en) 2015-11-05 2021-06-01 Juno Therapeutics, Inc. Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy
MA44314A (fr) 2015-11-05 2018-09-12 Juno Therapeutics Inc Récepteurs chimériques contenant des domaines induisant traf, et compositions et méthodes associées
EP3383892B1 (en) 2015-12-03 2022-12-21 Juno Therapeutics, Inc. Modified chimeric receptors and related compositions and methods
ES2928167T3 (es) 2015-12-03 2022-11-15 Juno Therapeutics Inc Composiciones y métodos para reducir las respuestas inmunitarias contra receptores de antígenos quiméricos
EP4012415A3 (en) 2015-12-04 2022-12-07 Juno Therapeutics, Inc. Methods and compositions related to toxicity associated with cell therapy
CN108699557B (zh) 2015-12-04 2025-08-15 诺华股份有限公司 用于免疫肿瘤学的组合物和方法
US11479755B2 (en) 2015-12-07 2022-10-25 2Seventy Bio, Inc. T cell compositions
US20180371052A1 (en) * 2015-12-22 2018-12-27 Icell Gene Therapeutics Llc Chimeric antigen receptors and enhancement of anti-tumor activity
WO2017120501A1 (en) 2016-01-07 2017-07-13 Mayo Foundation For Medical Education And Research Methods of treating cancer with interferon
EP3430549A1 (en) 2016-03-16 2019-01-23 Juno Therapeutics, Inc. Methods for adaptive design of a treatment regimen and related treatments
MA43758A (fr) 2016-03-16 2018-11-28 Yuan Ji Procédés pour déterminer le dosage d'un agent thérapeutique et traitements associés
MX2018011480A (es) 2016-03-22 2019-03-28 Seattle Children´S Hospital Dba Seattle Children´S Res Institute Metodos de intervencion temprana para prevenir o aminorar toxicidad.
WO2017173091A1 (en) 2016-03-30 2017-10-05 Musc Foundation For Research Development Methods for treatment and diagnosis of cancer by targeting glycoprotein a repetitions predominant (garp) and for providing effective immunotherapy alone or in combination
JP7282521B2 (ja) 2016-04-08 2023-05-29 パーデュー・リサーチ・ファウンデイション Ｃａｒ ｔ細胞療法のための方法および組成物
KR20190038479A (ko) 2016-05-06 2019-04-08 주노 쎄러퓨티크스 인코퍼레이티드 유전자 조작된 세포 및 그의 제조방법
US11400116B2 (en) 2016-05-06 2022-08-02 The Regents Of The University Of California Systems and methods for targeting cancer cells
CN109477830A (zh) * 2016-05-25 2019-03-15 昆士兰医学研究所理事会 免疫疗法的方法
CA3025523A1 (en) 2016-05-27 2017-11-30 Aadigen, Llc Peptides and nanoparticles for intracellular delivery of genome-editing molecules
EP4011381A1 (en) 2016-06-03 2022-06-15 Memorial Sloan-Kettering Cancer Center Adoptive cell therapies as early treatment options
MA45341A (fr) 2016-06-06 2019-04-10 Hutchinson Fred Cancer Res Procédés de traitement de malignités de lymphocytes b au moyen d'une thérapie cellulaire adoptive
US20200283534A1 (en) 2016-06-24 2020-09-10 iCell Gene Therapeuticics LLC CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS THEREOF
MA45491A (fr) 2016-06-27 2019-05-01 Juno Therapeutics Inc Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
CA3028002A1 (en) 2016-06-27 2018-01-04 Juno Therapeutics, Inc. Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
JP7086928B2 (ja) * 2016-07-25 2022-06-20 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 改変されたナチュラルキラー細胞を生成する方法および使用方法
ES2926513T3 (es) 2016-07-29 2022-10-26 Juno Therapeutics Inc Métodos para evaluar la presencia o ausencia de virus competente en replicación
WO2018023100A2 (en) 2016-07-29 2018-02-01 Juno Therapeutics, Inc. Anti-idiotypic antibodies and related methods
WO2018023093A1 (en) 2016-07-29 2018-02-01 Juno Therapeutics, Inc. Immunomodulatory polypeptides and related compositions and methods
EP3494138A1 (en) 2016-08-02 2019-06-12 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
CA3032429A1 (en) * 2016-08-03 2018-02-08 Washington University Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
EP3344263A4 (en) * 2016-08-04 2020-07-01 Memorial Sloan-Kettering Cancer Center CANCER ANTIGEN TARGETS AND USES THEREOF
SG10201913583QA (en) 2016-08-23 2020-02-27 Univ California Proteolytically cleavable chimeric polypeptides and methods of use thereof
AU2017319151B2 (en) 2016-08-30 2024-01-11 Memorial Sloan Kettering Cancer Center Immune cell compositions and methods of use for treating viral and other infections
AU2017322752A1 (en) 2016-09-12 2019-03-21 Juno Therapeutics, Inc. Perfusion bioreactor bag assemblies
EP3518943A4 (en) 2016-09-28 2020-04-22 Atossa Therapeutics, Inc. METHOD FOR ADAPTIVE CELL THERAPY
AU2017338827B2 (en) 2016-10-03 2023-08-31 Juno Therapeutics, Inc. HPV-specific binding molecules
GB2564823B8 (en) 2016-10-07 2022-06-29 Tcr2 Therapeutics Inc Compositions and methods for TCR reprogramming using fusion proteins
CA3037387A1 (en) 2016-10-13 2018-04-19 Juno Therapeutics, Inc. Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
MX2019005029A (es) 2016-11-03 2019-10-24 Juno Therapeutics Inc Terapia de combinación de una terapia de células t y un inhibidor de tirosina cinasa de bruton (btk).
MA46716A (fr) 2016-11-03 2019-09-11 Juno Therapeutics Inc Polythérapie de thérapie cellulaire et d'inhibiteur de la microglie
JP7093346B2 (ja) 2016-11-04 2022-06-29 ２セブンティ バイオ インコーポレイテッド 抗ｂｃｍａ ｃａｒ ｔ細胞組成物
CA3044593A1 (en) 2016-11-22 2018-05-31 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
EP3548622A1 (en) 2016-12-02 2019-10-09 Juno Therapeutics, Inc. Engineered b cells and related compositions and methods
KR20190104529A (ko) 2016-12-03 2019-09-10 주노 쎄러퓨티크스 인코퍼레이티드 Car-t 세포의 조절 방법
EP4279136A3 (en) 2016-12-03 2024-03-20 Juno Therapeutics, Inc. Methods for determining car-t cells dosing
WO2018102785A2 (en) 2016-12-03 2018-06-07 Juno Therapeutics, Inc. Methods and compositions for use of therapeutic t cells in combination with kinase inhibitors
MX2019006438A (es) 2016-12-05 2019-11-28 Juno Therapeutics Inc Produccion de celulas modificadas para terapia de celulas adoptivas.
CN110291200B (zh) 2016-12-12 2024-05-14 西雅图儿童医院（Dba西雅图儿童研究所） 对哺乳动物细胞中转基因表达的药剂配体诱导具有增大的灵敏度的嵌合转录因子变异体
EP3336107A1 (en) 2016-12-15 2018-06-20 Miltenyi Biotec GmbH Immune cells expressing an antigen binding receptor and a chimeric costimulatory receptor
CN106749677B (zh) * 2017-01-04 2020-06-12 上海交通大学医学院附属瑞金医院 一种靶向mll白血病的双特异性嵌合抗原受体基因及其应用
AU2018207305A1 (en) 2017-01-10 2019-07-25 Juno Therapeutics, Inc. Epigenetic analysis of cell therapy and related methods
JP2020505034A (ja) 2017-01-20 2020-02-20 ジュノ セラピューティクス ゲーエムベーハー 細胞表面コンジュゲートならびに関連する細胞組成物および方法
IL268349B2 (en) 2017-02-17 2024-08-01 Hutchinson Fred Cancer Res Combination therapies for treatment of bcma-related cancers and autoimmune disorders
EP4353818A3 (en) 2017-02-27 2024-06-19 Juno Therapeutics, Inc. Compositions, articles of manufacture and methods related to dosing in cell therapy
WO2018160622A1 (en) 2017-02-28 2018-09-07 Endocyte, Inc. Compositions and methods for car t cell therapy
CA3055539A1 (en) 2017-03-08 2018-09-13 Memorial Sloan Kettering Cancer Center Immune cell compositions and methods of use
KR102771581B1 (ko) 2017-03-14 2025-02-25 주노 쎄러퓨티크스 인코퍼레이티드 극저온 보관 방법
WO2018167486A1 (en) 2017-03-15 2018-09-20 Oxford Biomedica (Uk) Limited Method
CN110832075A (zh) 2017-03-22 2020-02-21 诺华股份有限公司 用于免疫肿瘤学的组合物和方法
JP2020515542A (ja) 2017-03-23 2020-05-28 ザ ジェネラル ホスピタル コーポレイション Ｃｘｃｒ４／ｃｘｃｒ７の遮断およびヒトパピローマウイルス関連疾患の治療
EP3600356A4 (en) 2017-03-27 2020-12-23 National University of Singapore TRUNCATED NKG2D CHEMERIC RECEPTORS AND THEIR USES IN NATURAL KILLER CELL IMMUNOTHERAPY
KR102624509B1 (ko) 2017-03-27 2024-01-12 싱가포르국립대학교 자연 살해 세포의 ex vivo 확장 및 활성화를 위한 자극성 세포주
RU2740438C1 (ru) 2017-04-05 2021-01-14 Корея Рисерч Инститьют Оф Байосайенс Энд Байотекнолоджи Активирующий nk-клетки слитый белок, nk-клетки и фармацевтическая композиция, включающая их
AU2018250336B2 (en) 2017-04-07 2025-02-20 Juno Therapeutics, Inc. Engineered cells expressing prostate-specific membrane antigen (PSMA) or a modified form thereof and related methods
CN110709700A (zh) 2017-04-14 2020-01-17 朱诺治疗学股份有限公司 评估细胞表面糖基化的方法
EP4083063A3 (en) 2017-04-18 2023-01-04 FUJIFILM Cellular Dynamics, Inc. Antigen-specific immune effector cells
JP7538601B2 (ja) * 2017-04-26 2024-08-22 ユーリカ セラピューティックス， インコーポレイテッド キメラ活性化受容体及びキメラ刺激受容体を発現する細胞並びにその使用
WO2018197949A1 (en) 2017-04-27 2018-11-01 Juno Therapeutics Gmbh Oligomeric particle reagents and methods of use thereof
PT3618842T (pt) 2017-05-01 2024-01-12 Juno Therapeutics Inc Combinação de uma terapia celular e de um composto imunomodulador
US11413310B2 (en) 2017-06-02 2022-08-16 Juno Therapeutics, Inc. Articles of manufacture and methods for treatment using adoptive cell therapy
EP3631468A1 (en) 2017-06-02 2020-04-08 Juno Therapeutics, Inc. Articles of manufacture and methods related to toxicity associated with cell therapy
DK3538645T3 (da) 2017-06-20 2021-04-19 Inst Curie Immunceller der mangler suv39h1
US12275787B2 (en) 2017-06-21 2025-04-15 Icell Gene Therapeutics Llc Chimeric antigen receptors (CARs), compositions and methods thereof
CN111373260A (zh) 2017-06-22 2020-07-03 得克萨斯大学体系董事会 产生调节性免疫细胞的方法及其用途
WO2019006427A1 (en) 2017-06-29 2019-01-03 Juno Therapeutics, Inc. WALL MODEL FOR ASSESSING TOXICITIES ASSOCIATED WITH IMMUNOTHERAPIES
CN118206655A (zh) 2017-07-25 2024-06-18 得克萨斯大学体系董事会 增强的嵌合抗原受体及其用途
KR20200064060A (ko) 2017-07-29 2020-06-05 주노 쎄러퓨티크스 인코퍼레이티드 재조합 수용체를 발현하는 세포 증폭용 시약
CN107326014B (zh) * 2017-07-31 2019-09-24 时力生物科技（北京）有限公司 一种双特异性嵌合抗原受体修饰的t淋巴细胞及其制备方法和应用
KR20250096881A (ko) 2017-08-09 2025-06-27 주노 쎄러퓨티크스 인코퍼레이티드 유전자 조작된 세포를 제조하기 위한 방법 및 조성물
AU2018313950A1 (en) 2017-08-09 2020-02-13 Juno Therapeutics, Inc. Methods for producing genetically engineered cell compositions and related compositions
MA50057A (fr) 2017-09-01 2020-07-08 Juno Therapeutics Inc Expression génique et évaluation d'un risque de développement d'une toxicité suite à une thérapie cellulaire
WO2019051335A1 (en) 2017-09-07 2019-03-14 Juno Therapeutics, Inc. METHODS OF IDENTIFYING CELLULAR CHARACTERISTICS RELATED TO RESPONSES ASSOCIATED WITH CELL THERAPY
CN109517820B (zh) 2017-09-20 2021-09-24 北京宇繁生物科技有限公司 一种靶向HPK1的gRNA以及HPK1基因编辑方法
US11952408B2 (en) 2017-10-03 2024-04-09 Juno Therapeutics, Inc. HPV-specific binding molecules
CN111433222B (zh) 2017-10-12 2025-01-28 得克萨斯大学体系董事会 用于免疫疗法的t细胞受体
US11564946B2 (en) 2017-11-01 2023-01-31 Juno Therapeutics, Inc. Methods associated with tumor burden for assessing response to a cell therapy
EP3704251A2 (en) 2017-11-01 2020-09-09 Editas Medicine, Inc. Methods, compositions and components for crispr-cas9 editing of tgfbr2 in t cells for immunotherapy
MA49911A (fr) 2017-11-01 2020-06-24 Juno Therapeutics Inc Anticorps et récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b
US11851679B2 (en) 2017-11-01 2023-12-26 Juno Therapeutics, Inc. Method of assessing activity of recombinant antigen receptors
US12031975B2 (en) 2017-11-01 2024-07-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
BR112020008638A2 (pt) 2017-11-01 2020-10-20 Juno Therapeutics Inc receptores de antígenos quiméricos específicos para antígenos de maturação de células b (bcma)
DK3704230T3 (da) 2017-11-01 2025-01-02 Juno Therapeutics Inc Fremgangsmåde til generering af terapeutiske sammensætninger af modificerede celler
US20210254000A1 (en) 2017-11-01 2021-08-19 Juno Therapeutics, Inc. Process for producing a t cell composition
CA3080109A1 (en) 2017-11-03 2019-05-09 Sorrento Therapeutics, Inc. Cd38-directed chimeric antigen receptor constructs
BR112020008812A2 (pt) 2017-11-06 2020-10-27 Juno Therapeutics Inc combinação de terapia celular e um inibidor de gama secretase
CN111556893A (zh) 2017-11-06 2020-08-18 爱迪塔斯医药股份有限公司 免疫疗法t细胞中cblb的crispr-cas9编辑的方法、组合物和组分
EP3706904A1 (en) 2017-11-10 2020-09-16 Juno Therapeutics, Inc. Closed-system cryogenic vessels
AU2018367452B2 (en) * 2017-11-14 2024-06-13 Memorial Sloan-Kettering Cancer Center IL-36 secreting immunoresponsive cells and uses thereof
US20210198372A1 (en) 2017-12-01 2021-07-01 Juno Therapeutics, Inc. Methods for dosing and for modulation of genetically engineered cells
US12139522B2 (en) 2017-12-05 2024-11-12 The Medical Research Infrastructure And Heal Serviced Fund Of The Tel Aviv Medecal Center T-cells comprising two different chimeric antigen receptors and uses thereof
IL274806B2 (en) 2017-12-05 2025-04-01 Medical Res Infrastructure & Health Services Fund Tel Aviv Medical Ct T cells containing chimeric receptors for CD138 and CD38 antigens and their use
SG11202005228YA (en) 2017-12-08 2020-07-29 Juno Therapeutics Inc Serum-free media formulation for culturing cells and methods of use thereof
JP2021505615A (ja) 2017-12-08 2021-02-18 ジュノー セラピューティクス インコーポレイテッド 細胞療法および関連方法のための表現型マーカー
KR102853341B1 (ko) 2017-12-08 2025-09-02 주노 쎄러퓨티크스 인코퍼레이티드 조작된 ｔ 세포의 조성물을 제조하는 방법
MA51184A (fr) 2017-12-15 2020-10-21 Juno Therapeutics Inc Molécules de liaison à l'anti-cct5 et procédés d'utilisation associés
CN109988242A (zh) * 2018-01-02 2019-07-09 武汉波睿达生物科技有限公司 联合嵌合抗原受体、表达载体、慢病毒及t细胞
CN111867619A (zh) 2018-01-03 2020-10-30 曲生物制品公司 过继性细胞治疗的先天寻靶
US11919937B2 (en) 2018-01-09 2024-03-05 Board Of Regents, The University Of Texas System T cell receptors for immunotherapy
CN110055275A (zh) * 2018-01-19 2019-07-26 科济生物医药（上海）有限公司 一种质粒载体对、其修饰的免疫细胞及其应用
CN112292138A (zh) 2018-01-22 2021-01-29 西雅图儿童医院（Dba西雅图儿童研究所） Car t细胞的使用方法
KR20200128014A (ko) 2018-01-31 2020-11-11 셀진 코포레이션 입양 세포 요법 및 체크포인트 억제제를 이용한 병용 요법
WO2019152747A1 (en) 2018-01-31 2019-08-08 Juno Therapeutics, Inc. Methods and reagents for assessing the presence or absence of replication competent virus
CN108314739B (zh) * 2018-02-05 2020-07-14 深圳市默赛尔生物医学科技发展有限公司 多信号嵌合抗原受体及其表达基因、其修饰的nk细胞及应用
JP7360174B2 (ja) 2018-02-09 2023-10-12 ナショナル ユニヴァーシティー オブ シンガポール ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用
EP3749687A4 (en) 2018-02-11 2021-12-29 Memorial Sloan Kettering Cancer Center Non-hla restricted t cell receptors and uses thereof
CN112041432A (zh) 2018-02-15 2020-12-04 纪念斯隆-凯特林癌症中心 Foxp3靶向剂组合物以及用于过继细胞疗法的使用方法
WO2019165237A1 (en) 2018-02-23 2019-08-29 Endocyte, Inc. Sequencing method for car t cell therapy
US20210046159A1 (en) 2018-03-09 2021-02-18 Ospedale San Raffaele S.R.L. Il-1 antagonist and toxicity induced by cell therapy
WO2019170147A1 (zh) 2018-03-09 2019-09-12 科济生物医药（上海）有限公司 用于治疗肿瘤的方法和组合物
US11827672B2 (en) * 2018-03-30 2023-11-28 Eureka Therapeutics, Inc. Constructs trageting CD22 and uses thereof
JP7334985B2 (ja) 2018-04-02 2023-08-29 ナショナル ユニヴァーシティー オブ シンガポール 免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和
US20210015869A1 (en) 2018-04-05 2021-01-21 Juno Therapeutics, Inc. T cells expressing a recombinant receptor, related polynucleotides and methods
CN112585276A (zh) 2018-04-05 2021-03-30 朱诺治疗学股份有限公司 产生表达重组受体的细胞的方法和相关组合物
RU2020135968A (ru) 2018-04-05 2022-05-06 Джуно Терапьютикс, Инк. T-клеточные рецепторы и модифицированные клетки, экспрессирующие
US12377147B2 (en) 2018-04-19 2025-08-05 Baylor College Of Medicine Reprogramming CD4 t cells into cytotoxic CD8 cells by forced expression of CD8ab and class 1 restricted t cell receptors
CN108864288A (zh) * 2018-04-26 2018-11-23 上海怡豪生物科技有限公司 乳腺癌的双靶点car-t治疗载体及其构建方法和应用
MX2020011527A (es) 2018-05-03 2021-02-26 Juno Therapeutics Inc Terapia de combinación de una terapia de células t-receptor de antígeno quimérico (car) y un inhibidor de cinasa.
MY208825A (en) 2018-06-13 2025-05-30 Novartis Ag Bcma chimeric antigen receptors and uses thereof
WO2019245991A1 (en) * 2018-06-18 2019-12-26 Eureka Therapeutics, Inc. Constructs targeting prostate-specific membrane antigen (psma) and uses thereof
CN110615843B (zh) * 2018-06-20 2023-05-09 上海隆耀生物科技有限公司 一种包含第三信号受体的嵌合抗原受体及其应用
AU2019310855A1 (en) 2018-07-24 2021-03-11 Crage Medical Co., Limited Method for treating tumor using immune effector cell
WO2020033927A2 (en) 2018-08-09 2020-02-13 Juno Therapeutics, Inc. Processes for generating engineered cells and compositions thereof
EA202190469A1 (ru) 2018-08-09 2021-06-28 Джуно Терапьютикс, Инк. Способы оценки интегрированных нуклеиновых кислот
CN112601758A (zh) 2018-08-29 2021-04-02 新加坡国立大学 特异性刺激经基因修饰免疫细胞的存活和扩增的方法
JP7558151B2 (ja) * 2018-09-05 2024-09-30 アダプティミューン・リミテッド Ｔ細胞改変
JP7504891B2 (ja) 2018-09-11 2024-06-24 ジュノー セラピューティクス インコーポレイテッド 操作された細胞組成物のマススペクトロメトリー分析のための方法
JP7716976B2 (ja) 2018-09-19 2025-08-01 フジフィルム セルラー ダイナミクス，インコーポレイテッド キメラ抗原受容体改変免疫細胞の活性化及び拡大培養のためのプロテインｌ
CA3117568A1 (en) 2018-10-31 2020-05-07 Juno Therapeutics Gmbh Methods for selection and stimulation of cells and apparatus for same
TW202021981A (zh) 2018-11-01 2020-06-16 美商奇諾治療有限公司 G蛋白偶合受體c類第5群成員d（gprc5d）特異性嵌合抗原受體
SG11202104188VA (en) 2018-11-01 2021-05-28 Juno Therapeutics Inc Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
CA3117720A1 (en) 2018-11-06 2020-05-14 Juno Therapeutics, Inc. Process for producing genetically engineered t cells
EP3876958A1 (en) 2018-11-08 2021-09-15 Juno Therapeutics, Inc. Methods and combinations for treatment and t cell modulation
BR112021009420A2 (pt) 2018-11-16 2021-11-23 Juno Therapeutics Inc Métodos de dosagem de células t manipuladas para o tratamento de malignidades de células b
WO2020106621A1 (en) 2018-11-19 2020-05-28 Board Of Regents, The University Of Texas System A modular, polycistronic vector for car and tcr transduction
AU2019386140A1 (en) 2018-11-28 2021-06-24 Board Of Regents, The University Of Texas System Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment
MX2021006393A (es) 2018-11-29 2021-10-13 Univ Texas Metodos para expansion ex vivo de celulas exterminadoras naturales y uso de las mismas.
EP3886875B1 (en) 2018-11-30 2024-05-08 Juno Therapeutics, Inc. Methods for treatment using adoptive cell therapy
MX2021006244A (es) 2018-11-30 2021-09-10 Juno Therapeutics Inc Metodos de dosificacion y tratamiento de canceres de celulas b en terapia celular adoptiva.
MA54863A (fr) 2019-01-29 2021-12-08 Juno Therapeutics Inc Anticorps et récepteurs antigéniques chimériques spécifiques du récepteur orphelin-1 de type récepteur à tyrosine kinase (ror1)
US20220170044A1 (en) * 2019-02-08 2022-06-02 Dna Twopointo, Inc. Transposon-based modifications of immune cells
AU2020226401A1 (en) * 2019-02-18 2021-10-14 Memorial Sloan-Kettering Cancer Center Combinations of multiple chimeric antigen receptors for immunotherapy
GB201902277D0 (en) 2019-02-19 2019-04-03 King S College London Therapeutic agents
CN118546959A (zh) 2019-03-05 2024-08-27 恩卡尔塔公司 Cd19定向性嵌合抗原受体及其在免疫疗法中的用途
US20220152110A1 (en) * 2019-03-22 2022-05-19 The Regents Of The University Of California Switchable Chimeric Antigen Receptor-Engineered Human Natural Killer Cells
AU2020272074A1 (en) * 2019-04-12 2021-11-25 The Trustees Of The University Of Pennsylvania Compositions and Methods Comprising a High Affinity Chimeric Antigen Receptor (CAR) with Cross-Reactivity to Clinically-Relevant EGFR Mutated Proteins
SG11202111130SA (en) 2019-04-30 2021-11-29 Senti Biosciences Inc Chimeric receptors and methods of use thereof
KR20220016475A (ko) 2019-05-01 2022-02-09 주노 쎄러퓨티크스 인코퍼레이티드 변형된 ｔｇｆｂｒ2 유전자 좌에서 재조합 수용체를 발현하는 세포, 관련 폴리뉴클레오티드 및 방법
EP3962519A1 (en) 2019-05-01 2022-03-09 Juno Therapeutics, Inc. Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods
AU2020287882A1 (en) 2019-06-07 2022-01-20 Juno Therapeutics, Inc. Automated T cell culture
CN114269371A (zh) 2019-06-12 2022-04-01 朱诺治疗学股份有限公司 细胞介导的细胞毒性疗法与促存活bcl2家族蛋白的抑制剂的组合疗法
US20220251572A1 (en) 2019-07-23 2022-08-11 Mnemo Therapeutics Immune cells defective for suv39h1
CN114555112A (zh) 2019-08-22 2022-05-27 朱诺治疗学股份有限公司 T细胞疗法和zeste增强子同源物2(ezh2)抑制剂的组合疗法及相关方法
CN114641308A (zh) * 2019-08-28 2022-06-17 伦敦国王学院 B细胞靶向的平行CAR(pCAR)治疗剂
KR20220073738A (ko) 2019-08-30 2022-06-03 주노 쎄러퓨티크스 인코퍼레이티드 세포 분류를 위한 기계 학습 방법
US20240082372A1 (en) 2019-09-02 2024-03-14 Institut Curie Immunotherapy targeting tumor neoantigenic peptides
US20220401539A1 (en) 2019-10-22 2022-12-22 Institut Curie Immunotherapy Targeting Tumor Neoantigenic Peptides
US20250237628A1 (en) 2019-10-30 2025-07-24 Juno Therapeutics Gmbh Cell selection and/or stimulation devices and methods of use
JP2022554348A (ja) 2019-11-05 2022-12-28 ジュノー セラピューティクス インコーポレイテッド 治療用ｔ細胞組成物の属性を決定する方法
CN114980918A (zh) 2019-11-07 2022-08-30 朱诺治疗学股份有限公司 T细胞疗法与(s)-3-[4-(4-吗啉-4-基甲基-苄氧基)-1-氧代-1,3-二氢-异吲哚-2-基]-哌啶-2,6-二酮的组合
IL292924A (en) 2019-11-26 2022-07-01 Novartis Ag Cd19 and cd22 chimeric antigen receptors and uses thereof
US20230192869A1 (en) 2019-12-06 2023-06-22 Juno Therapeutics, Inc. Anti-idiotypic antibodies to gprc5d-targeted binding domains and related compositions and methods
JP2023504740A (ja) 2019-12-06 2023-02-06 ジュノー セラピューティクス インコーポレイテッド Ｂｃｍａ標的結合ドメインに対する抗イディオタイプ抗体ならびに関連する組成物および方法
CN115398231A (zh) 2019-12-06 2022-11-25 朱诺治疗学股份有限公司 与治疗b细胞恶性肿瘤的细胞疗法相关的毒性和反应的相关方法
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
EP4093433A1 (en) 2020-01-24 2022-11-30 Juno Therapeutics, Inc. Methods for dosing and treatment of follicular lymphoma and marginal zone lymphoma in adoptive cell therapy
EP4097218A1 (en) 2020-01-28 2022-12-07 Juno Therapeutics, Inc. Methods for t cell transduction
CN115361955A (zh) 2020-02-12 2022-11-18 朱诺治疗学股份有限公司 针对bcma的嵌合抗原受体t细胞组合物及其方法和用途
WO2021163391A1 (en) 2020-02-12 2021-08-19 Juno Therapeutics, Inc. Cd19-directed chimeric antigen receptor t cell compositions and methods and uses thereof
US20230106973A1 (en) 2020-02-17 2023-04-06 Board Of Regents, The University Of Texas System Methods for expansion of tumor infiltrating lymphocytes and use thereof
WO2021164959A1 (en) * 2020-02-17 2021-08-26 Miltenyi Biotec B.V. & Co. KG Method for providing personalized cells with chimeric antigen receptors (car) against tumor microenvironment cells
WO2021207689A2 (en) 2020-04-10 2021-10-14 Juno Therapeutics, Inc. Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting b-cell maturation antigen
IL297688A (en) 2020-04-28 2022-12-01 Juno Therapeutics Inc Combination of bcma-directed t cell therapy and an immunomodulatory compound
WO2021228999A1 (en) 2020-05-12 2021-11-18 Institut Curie Neoantigenic epitopes associated with sf3b1 mutations
KR20230022868A (ko) 2020-05-13 2023-02-16 주노 쎄러퓨티크스 인코퍼레이티드 재조합 수용체를 발현하는 공여자-배치 세포의 제조 방법
EP4150640A1 (en) 2020-05-13 2023-03-22 Juno Therapeutics, Inc. Methods of identifying features associated with clinical response and uses thereof
EP4153301A2 (en) 2020-05-21 2023-03-29 Board of Regents, The University of Texas System T cell receptors with vgll1 specificity and uses thereof
WO2021260186A1 (en) 2020-06-26 2021-12-30 Juno Therapeutics Gmbh Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
WO2022016119A1 (en) 2020-07-17 2022-01-20 Simurx, Inc. Chimeric myd88 receptors for redirecting immunosuppressive signaling and related compositions and methods
WO2022016112A1 (en) 2020-07-17 2022-01-20 Instil Bio (Uk) Limited Receptors providing targeted costimulation for adoptive cell therapy
US20230303974A1 (en) 2020-07-30 2023-09-28 Institut Curie Immune Cells Defective for SOCS1
WO2022029660A1 (en) 2020-08-05 2022-02-10 Juno Therapeutics, Inc. Anti-idiotypic antibodies to ror1-targeted binding domains and related compositions and methods
AU2021329453A1 (en) 2020-08-21 2023-03-16 12343096 Canada Inc. Modular assembly receptors and uses thereof
MX2023004598A (es) 2020-10-23 2023-06-29 Asher Biotherapeutics Inc Fusiones con moléculas de unión al antígeno cd8 para modular la función de las células inmunitarias.
US20230398148A1 (en) 2020-11-04 2023-12-14 Juno Therapeutics, Inc. Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods
GB2617474A (en) 2020-11-04 2023-10-11 Myeloid Therapeutics Inc Engineered chimeric fusion protein compositions and methods of use thereof
WO2022104109A1 (en) 2020-11-13 2022-05-19 Catamaran Bio, Inc. Genetically modified natural killer cells and methods of use thereof
US20220162288A1 (en) 2020-11-25 2022-05-26 Catamaran Bio, Inc. Cellular therapeutics engineered with signal modulators and methods of use thereof
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
EP4255922A1 (en) 2020-12-03 2023-10-11 Century Therapeutics, Inc. Genetically engineered cells and uses thereof
WO2022133030A1 (en) 2020-12-16 2022-06-23 Juno Therapeutics, Inc. Combination therapy of a cell therapy and a bcl2 inhibitor
JP2024500847A (ja) 2020-12-18 2024-01-10 センチュリー セラピューティクス，インコーポレイテッド 適合可能な受容体特異性を有するキメラ抗原受容体システム
JP2024503027A (ja) 2021-01-11 2024-01-24 サナ バイオテクノロジー，インコーポレイテッド Ｃｄ８標的ウイルスベクターの使用方法
JP2024509853A (ja) 2021-03-03 2024-03-05 ジュノー セラピューティクス インコーポレイテッド Ｔ細胞療法およびｄｇｋ阻害剤の組合せ
JP2024510982A (ja) 2021-03-11 2024-03-12 ムネモ・セラピューティクス 腫瘍ネオ抗原ペプチド
US20250352577A1 (en) 2021-03-11 2025-11-20 Mnemo Therapeutics Tumor neoantigenic peptides and uses thereof
CA3213002A1 (en) 2021-03-11 2022-09-15 Institut Curie Transmembrane neoantigenic peptides
GB2623191A (en) 2021-03-17 2024-04-10 Myeloid Therapeutics Inc Engineered chimeric fusion protein compositions and methods of use thereof
AU2022244229A1 (en) 2021-03-22 2023-09-14 Juno Therapeutics, Inc. Method to assess potency of viral vector particles
KR20230159851A (ko) 2021-03-22 2023-11-22 주노 쎄러퓨티크스 인코퍼레이티드 치료 세포 조성물의 효력을 결정하는 방법
MX2023011370A (es) 2021-03-29 2023-11-24 Juno Therapeutics Inc Combinacion de una terapia con celulas t con receptores de antigenos quimericos (car) y un compuesto inmunomodulador para el tratamiento de linfoma.
AU2022246593A1 (en) 2021-03-29 2023-10-12 Juno Therapeutics, Inc. Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy
CA3214280A1 (en) 2021-04-16 2022-10-20 Julie Ann RYTLEWSKI T cell therapy in patients who have had prior stem cell transplant
CA3214683A1 (en) 2021-04-16 2022-10-20 Julie Ann RYTLEWSKI Combination therapies with bcma-directed t cell therapy
CN117545492A (zh) 2021-04-22 2024-02-09 贝勒医学院 工程改造具有减少的自相残杀活性的免疫细胞的方法
US20250283037A1 (en) 2021-05-06 2025-09-11 Juno Therapeutics Gmbh Methods for stimulating and transducing t cells
WO2022238386A1 (en) 2021-05-10 2022-11-17 Institut Curie Methods for the treatment of cancer, inflammatory diseases and autoimmune diseases
GB2623653A (en) 2021-05-11 2024-04-24 Myeloid Therapeutics Inc Methods and compositions for genomic integration
WO2022248602A1 (en) 2021-05-25 2022-12-01 Institut Curie Myeloid cells overexpressing bcl2
WO2022266192A1 (en) 2021-06-16 2022-12-22 Instil Bio, Inc. Receptors providing targeted costimulation for adoptive cell therapy
EP4370213A4 (en) 2021-07-16 2025-06-04 Instil Bio (Uk) Limited Chimeric molecules for targeted costimulation for adoptive cell therapy
IL310550A (en) 2021-08-04 2024-03-01 Univ Colorado Regents LAT-activating chimeric antigen receptor T cells and methods of using them
TW202321457A (zh) 2021-08-04 2023-06-01 美商薩那生物科技公司 靶向ｃｄ４之病毒載體之用途
WO2023019213A1 (en) * 2021-08-13 2023-02-16 Simcere Innovation, Inc. Three-dimensional culturing of pluripotent stem cells to produce hematopoietic stem cells
EP4426339A1 (en) 2021-11-03 2024-09-11 Celgene Corporation Chimeric antigen receptors specific for b-cell maturation antigen for use in treating myeloma
WO2023081715A1 (en) 2021-11-03 2023-05-11 Viracta Therapeutics, Inc. Combination of car t-cell therapy with btk inhibitors and methods of use thereof
WO2023081900A1 (en) 2021-11-08 2023-05-11 Juno Therapeutics, Inc. Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
EP4444874A1 (en) 2021-12-09 2024-10-16 Zygosity Limited Vector
EP4448578A1 (en) 2021-12-17 2024-10-23 Shanghai Henlius Biotech, Inc. Anti-ox40 antibodies, multispecific antibodies and methods of use
KR20240122784A (ko) 2021-12-17 2024-08-13 상하이 헨리우스 바이오테크, 인크. 항-ox40 항체 및 사용 방법
WO2023115041A1 (en) 2021-12-17 2023-06-22 Sana Biotechnology, Inc. Modified paramyxoviridae attachment glycoproteins
US20250059239A1 (en) 2021-12-17 2025-02-20 Sana Biotechnology, Inc. Modified paramyxoviridae fusion glycoproteins
WO2023126458A1 (en) 2021-12-28 2023-07-06 Mnemo Therapeutics Immune cells with inactivated suv39h1 and modified tcr
CN120077132A (zh) 2022-01-21 2025-05-30 姆内莫治疗公司 Rna对suv39h1表达的调控
US20250101379A1 (en) 2022-01-28 2025-03-27 Juno Therapeutics, Inc. Methods of manufacturing cellular compositions
WO2023150518A1 (en) 2022-02-01 2023-08-10 Sana Biotechnology, Inc. Cd3-targeted lentiviral vectors and uses thereof
CN119031931A (zh) 2022-02-22 2024-11-26 朱诺治疗学股份有限公司 蛋白酶3（pr3）嵌合自身抗体受体t细胞及相关方法和用途
EP4493584A1 (en) 2022-03-18 2025-01-22 The Regents of the University of Colorado, a body corporate Genetically engineered t-cell co-receptors and methods of use thereof
EP4499134A1 (en) 2022-03-24 2025-02-05 Institut Curie Immunotherapy targeting tumor transposable element derived neoantigenic peptides in glioblastoma
KR20240163119A (ko) 2022-03-25 2024-11-18 상하이 헨리우스 바이오테크, 인크. 항-msln 항체 및 사용 방법
EP4499677A1 (en) 2022-03-31 2025-02-05 Institut Curie Modified rela protein for inducing interferon expression and engineered immune cells with improved interferon expression
US20250222027A1 (en) 2022-04-01 2025-07-10 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
US20250304913A1 (en) 2022-04-06 2025-10-02 The Regents Of The University Of Colorado, A Body Corporate Chimeric antigen receptor t cells and methods of use thereof
WO2023196921A1 (en) 2022-04-06 2023-10-12 The Regents Of The University Of Colorado, A Body Corporate Granzyme expressing t cells and methods of use
US20250235478A1 (en) 2022-04-28 2025-07-24 Musc Foundation For Research Development Chimeric antigen receptor modified regulatory t cells for treating cancer
US20250297282A1 (en) 2022-05-05 2025-09-25 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use
US20250302954A1 (en) 2022-05-11 2025-10-02 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
KR20250008774A (ko) 2022-05-11 2025-01-15 셀진 코포레이션 T 세포 요법 및 그의 생산과 관련된 방법 및 용도
US20250339464A1 (en) 2022-05-16 2025-11-06 Miltenyi Biotec B.V. & Co. KG Endogenous signaling molecule activating chimeric antigen receptors and methods of generation thereof
EP4279085A1 (en) 2022-05-20 2023-11-22 Mnemo Therapeutics Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious disease
EP4532695A1 (en) 2022-05-25 2025-04-09 Celgene Corporation Methods of manufacturing t cell therapies
WO2023230548A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Method for predicting response to a t cell therapy
CN115058387B (zh) * 2022-06-11 2023-12-01 重庆医科大学 一种人胚胎干细胞与前列腺癌细胞共培养制备抗前列腺癌药物的方法
EP4543923A1 (en) 2022-06-22 2025-04-30 Juno Therapeutics, Inc. Treatment methods for second line therapy of cd19-targeted car t cells
WO2024006960A1 (en) 2022-06-29 2024-01-04 Juno Therapeutics, Inc. Lipid nanoparticles for delivery of nucleic acids
WO2024031091A2 (en) 2022-08-05 2024-02-08 Juno Therapeutics, Inc. Chimeric antigen receptors specific for gprc5d and bcma
IL318749A (en) 2022-08-26 2025-04-01 Juno Therapeutics Inc Delta-like ligand 3 (DLL3)-specific chimeric antigen receptors and antibodies
WO2024054944A1 (en) 2022-09-08 2024-03-14 Juno Therapeutics, Inc. Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing
CN117736335A (zh) * 2022-09-20 2024-03-22 深圳先进技术研究院 靶向间皮素和nkg2d配体的双靶向car-t细胞及其应用
WO2024062138A1 (en) 2022-09-23 2024-03-28 Mnemo Therapeutics Immune cells comprising a modified suv39h1 gene
WO2024081820A1 (en) 2022-10-13 2024-04-18 Sana Biotechnology, Inc. Viral particles targeting hematopoietic stem cells
WO2024097905A1 (en) 2022-11-02 2024-05-10 Celgene Corporation Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
EP4615960A1 (en) 2022-11-09 2025-09-17 C3S2 GmbH Methods for manufacturing engineered immune cells
WO2024102948A1 (en) 2022-11-11 2024-05-16 Celgene Corporation Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods
KR20250121074A (ko) 2022-12-09 2025-08-11 주노 쎄러퓨티크스 인코퍼레이티드 홀로그래픽 이미징을 사용하여 세포 표현형을 예측하기 위한 기계 학습 방법
AR131320A1 (es) 2022-12-13 2025-03-05 Juno Therapeutics Inc Receptores de antígenos quiméricos específicos para baff-r y cd19 y métodos y usos de los mismos
TW202430215A (zh) 2022-12-14 2024-08-01 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 用於將治療劑遞送至骨之組成物和方法
EP4658675A1 (en) 2023-02-03 2025-12-10 C3S2 GmbH Methods for non-viral manufacturing of engineered immune cells
IL322815A (en) 2023-02-28 2025-10-01 Juno Therapeutics Inc Cell therapy for the treatment of systemic autoimmune diseases
IL322949A (en) 2023-03-03 2025-10-01 Arsenal Biosciences Inc Systems targeting PSMA and CA9
WO2024220560A1 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Engineered protein g fusogens and related lipid particles and methods thereof
WO2024220598A2 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Lentiviral vectors with two or more genomes
WO2024220588A1 (en) 2023-04-18 2024-10-24 Juno Therapeutics, Inc. Cytotoxicity assay for assessing potency of therapeutic cell compositions
WO2024220574A1 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Universal protein g fusogens and adapter systems thereof and related lipid particles and uses
WO2024226858A1 (en) 2023-04-26 2024-10-31 Juno Therapeutics, Inc. Methods for viral vector manufacturing
WO2024243365A2 (en) 2023-05-23 2024-11-28 Juno Therapeutics, Inc. Activation markers of t cells and method for assessing t cell activation
WO2025054202A1 (en) 2023-09-05 2025-03-13 Sana Biotechnology, Inc. Method of screening a sample comprising a transgene with a unique barcode
EP4520334A1 (en) 2023-09-07 2025-03-12 Mnemo Therapeutics Methods and compositions for improving immune response
WO2025052001A1 (en) 2023-09-07 2025-03-13 Mnemo Therapeutics Methods and compositions for improving immune response
WO2025059362A1 (en) 2023-09-13 2025-03-20 Juno Therapeutics, Inc. Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses
WO2025076472A1 (en) 2023-10-06 2025-04-10 Juno Therapeutics, Inc. Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses
WO2025097055A2 (en) 2023-11-02 2025-05-08 The Broad Institute, Inc. Compositions and methods of use of t cells in immunotherapy
WO2025096975A1 (en) 2023-11-02 2025-05-08 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods of enhancing immune cell therapies by runx2 modulation
WO2025128434A1 (en) 2023-12-14 2025-06-19 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for the treatment of ven/aza resistant acute myeloid leukemia
WO2025147545A1 (en) 2024-01-03 2025-07-10 Juno Therapeutics, Inc. Lipid nanoparticles for delivery of nucleic acids and related methods and uses
WO2025151838A1 (en) 2024-01-12 2025-07-17 Sana Biotechnology, Inc. Safety switches to control in vitro and in vivo proliferation of cell therapy products
WO2025163107A1 (en) 2024-02-01 2025-08-07 Institut Gustave Roussy Immune cells defective for znf217 and uses thereof
WO2025184421A1 (en) 2024-02-28 2025-09-04 Juno Therapeutics, Inc. Chimeric antigen receptors and antibodies specific for delta-like ligand 3 (dll3) and related methods
WO2025212519A1 (en) 2024-04-01 2025-10-09 Moonlight Bio, Inc. Dll3 binding proteins and uses thereof
WO2025235851A1 (en) 2024-05-10 2025-11-13 Juno Therapeutics, Inc. Genetically engineered t cells expressing a cd19 chimeric antigen receptor (car) and uses thereof for allogeneic cell therapy
NL2037811B1 (en) 2024-05-29 2025-12-12 Univ Oslo Treatment for Cancer
WO2025259108A1 (en) 2024-06-11 2025-12-18 Prinses Máxima Centrum Voor Kinderoncologie B.V. Brain organoid

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5712149A (en) 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
GB9605515D0 (en) 1996-03-15 1996-05-15 Medical Res Council Improvements in or relating to cell stimulation
US7446190B2 (en) * 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US7629440B2 (en) * 2002-08-20 2009-12-08 Genitrix, Llc Lectin compositions and methods for modulating an immune response to an antigen
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
US20050113564A1 (en) * 2003-11-05 2005-05-26 St. Jude Children's Research Hospital Chimeric receptors with 4-1BB stimulatory signaling domain
PT2856876T (pt) * 2007-03-30 2018-03-28 Memorial Sloan Kettering Cancer Center Expressão constitutiva de ligantes co-estimulatórios em linfócitos t adotivamente transferidos
US8315214B2 (en) 2007-05-18 2012-11-20 Research In Motion Limited Method and system for discontinuous reception de-synchronization detection
US20140088019A1 (en) * 2011-02-11 2014-03-27 Zyngenia, Inc. Monovalent and Multivalent Multispecific Complexes and Uses Thereof
GB201108236D0 (en) * 2011-05-17 2011-06-29 Ucl Business Plc Method
EA201490364A1 (ru) * 2011-07-29 2014-08-29 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Костимулирующие рецепторы-переключатели
EP2903637B1 (en) * 2012-10-02 2019-06-12 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
US10117896B2 (en) * 2012-10-05 2018-11-06 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
JP6396306B2 (ja) 2012-11-09 2018-09-26 ディーエスエム アイピー アセッツ ビー．ブイ．Ｄｓｍ Ｉｐ Ａｓｓｅｔｓ Ｂ．Ｖ． リグノセルロース系材料の酵素加水分解および糖類発酵のための方法
KR102417657B1 (ko) 2013-02-06 2022-07-07 안트로제네시스 코포레이션 개선된 특이성을 갖는 변경된 t 림프구
EP2970426B1 (en) 2013-03-15 2019-08-28 Michael C. Milone Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy

Also Published As

Publication number Publication date
ES2743738T3 (es) 2020-02-20
MX2015004287A (es) 2016-03-01
IL238047B (en) 2020-02-27
EP2903637A1 (en) 2015-08-12
JP2020096625A (ja) 2020-06-25
JP6963051B2 (ja) 2021-11-05
MX370148B (es) 2019-12-03
IL272539A (en) 2020-03-31
US20200317781A1 (en) 2020-10-08
RU2015116901A (ru) 2016-11-27
RU2729401C2 (ru) 2020-08-06
CA2886859C (en) 2022-05-17
US11712469B2 (en) 2023-08-01
EP3597215A1 (en) 2020-01-22
AU2013327136A1 (en) 2015-04-16
US20250186585A1 (en) 2025-06-12
PH12015500747A1 (en) 2015-05-25
US20150342993A1 (en) 2015-12-03
NZ746914A (en) 2020-03-27
CN104853766A (zh) 2015-08-19
WO2014055668A1 (en) 2014-04-10
KR20150063145A (ko) 2015-06-08
AU2018204297A1 (en) 2018-07-05
AU2018204297B2 (en) 2020-10-01
US12263220B2 (en) 2025-04-01
PH12019502424A1 (en) 2021-09-01
RU2020124583A (ru) 2020-08-03
IL272539B (en) 2021-02-28
AU2020294287B2 (en) 2023-06-08
US20240091353A1 (en) 2024-03-21
HK1208631A1 (en) 2016-03-11
ZA201502880B (en) 2020-11-25
IL238047A0 (en) 2015-05-31
AU2020294287A1 (en) 2021-01-28
SG11201502598SA (en) 2015-05-28
EP2903637B1 (en) 2019-06-12
JP2022024161A (ja) 2022-02-08
JP6441802B2 (ja) 2018-12-19
PH12015500747B1 (en) 2021-04-14
JP2020078331A (ja) 2020-05-28
US10654928B2 (en) 2020-05-19
KR102198058B1 (ko) 2021-01-06
CN112430580A (zh) 2021-03-02
JP2018108111A (ja) 2018-07-12
CN112458057A (zh) 2021-03-09
JP2015535689A (ja) 2015-12-17
EP2903637A4 (en) 2016-10-19
CA2886859A1 (en) 2014-04-10

Similar Documents

Publication Publication Date Title
PH12019502424A1 (en) Compositions and methods for immunotherapy
ZA202306503B (en) Compositions and methods for immunotherapy
MY175869A (en) Compositions and methods for immunotherapy
den Haan et al. The activation of the adaptive immune system: cross-talk between antigen-presenting cells, T cells and B cells
MX2022012082A (es) Direccion de celulas citotoxicas con receptores quimericos para inmunoterapia adoptiva.
NZ743310A (en) Method and compositions for cellular immunotherapy
MX2017007138A (es) Metodos y composiciones para terapia celular adoptiva.
MX2016012713A (es) Inmunoreceptores especificos de claudina-6 y epitopos de celulas t.
NZ725201A (en) Improved methods for manufacturing adoptive cell therapies
WO2014145252A3 (en) Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
HK1255161A1 (zh) 用於过继性细胞治疗的工程细胞
MY181834A (en) Treatment of cancer using humanized anti-bcma chimeric antigen receptor
WO2016011210A3 (en) Engineered cells for adoptive cell therapy
MX374929B (es) RECEPTOR QUIMERICO DE ANTIGENO anti-EGFRvlll HUMANIZADO Y USOS DEL MISMO.
EP4303229A3 (en) Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
HK1243631A1 (zh) 用於提高过继细胞免疫疗法效力的组合物和方法
IL251196A0 (en) Chimeric antigen receptor T cells target il13ra2
MX2017001013A (es) Tratamiento de cáncer usando un receptor quimérico de antígeno cll-1.
MX2020012742A (es) Metodo y composiciones para inmunoterapia celular.
NZ700362A (en) Chimeric antigen receptors targeting b-cell maturation antigen
MX360772B (es) Anticuerpos cd47 y metodos de uso de los mismos.
SG11202003849VA (en) Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells
EP4295914A3 (en) Genetically-engineered drug resistant t cells and methods of using the same
MX2015004892A (es) Metodos y composiciones que se relacionan con anticuerpos de receptor anti-il-21.
HK40109813A (zh) 用於同种异体嵌合抗原受体t细胞的给药的方法和组合物

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 OCT 2021 BY CPA GLOBAL

Effective date: 20200904

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 OCT 2022 BY CPA GLOBAL

Effective date: 20210902

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 OCT 2023 BY CPA GLOBAL

Effective date: 20220902

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 OCT 2024 BY CPA GLOBAL

Effective date: 20230831

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 OCT 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20240829